Blade Therapeutics: Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), today announced that it has made a submission to the United States Securities and Exchange Commission ("SEC") of a prospectus supplement containing information supplements and updates to the information contained in the proxy statement/prospectus dated May 9, 2022.